HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only appendix Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Reid, R. L Search for Related Content PubMed PubMed Citation Articles by Reid, R. L Topic Collections Relevant Article

Hormone therapy for younger women may not increase CHD risk during 5–7 years follow-up, but stroke risk was increased independent of age

Clinical impact ratings GP/FP/Primary care Gynaecology Cardiology IM/Ambulatory care

Key Words: cardiovascular diseases • oestrogen replacement therapy

The first 150 words of the full text of this article appear below.

METHODS
Design: 2 randomised placebo-controlled trials (Women’s Health Initiative [WHI] trials).

Allocation: {concealed}^*.

Blinding: blinded {clinicians, participants, data collectors, outcome assessors, and monitoring committee}^*.

Follow-up period: mean 5.6 and 7.1 years.

Setting: 40 US clinical centres.

Participants: 27 347 predominantly healthy postmenopausal women 50–79 years of age (mean age 63^* and 64^|| y).

Intervention conjugated equine oestrogen (CEO), 0.625 mg/day, plus medroxyprogesterone acetate, 2.5 mg/day (n = 8506), or placebo (n = 8102) in women with an intact uterus; CEO, 0.625 mg/day (n = 5310), or placebo (n = 5429) in women with a hysterectomy.

Outcomes: coronary heart disease (CHD) (myocardial infarction or CHD death), stroke, total mortality, and a global index.

Participant follow-up: 94%^|| (intention-to-treat analysis).

MAIN RESULTS
Overall, the HT and placebo groups did not differ for CHD, total mortality, and the global index; the risk of stroke was higher in the HT group (hazard ratio 1.3, CI 1.1 . . . [Full text of this article]

Robert L Reid, MD

Queen’s University,
Kingston, Ontario, Canada

Relevant Article

Glossary
Evid. Based Med. 2007 12: 160. (in Glossary) [Extract] [Full Text] [PDF]